Exploration of HIV-1 fusion peptide–antibody VRC34.01 binding reveals fundamental neutralization sites

2019 ◽  
Vol 21 (34) ◽  
pp. 18569-18576
Author(s):  
Mei Feng ◽  
David R. Bell ◽  
Hongsuk Kang ◽  
Qiwen Shao ◽  
Ruhong Zhou
Keyword(s):  
Binding Affinity ◽  
Envelope Glycoprotein ◽  
Fusion Peptide ◽  
Antibody Binding ◽  
Peptide Antibody ◽  
Hiv Neutralization ◽  
Hiv Envelope ◽  
Hiv 1

VRC34.01 antibody binding to a vulnerable site of HIV envelope glycoprotein (Env), the gp41 fusion peptide, renders robust HIV neutralization, but several critical mutations decrease binding affinity and result in unbinding.

scholarly journals HIV envelope tail truncation confers resistance to SERINC5 restriction

2021 ◽  
Vol 118 (21) ◽  
pp. e2101450118
Author(s):  
Tafhima Haider ◽  
Xenia Snetkov ◽  
Clare Jolly
Keyword(s):  
T Cells ◽  
Envelope Glycoprotein ◽  
Cytoplasmic Tail ◽  
Restriction Factor ◽  
Viral Fusion ◽  
Restriction Factors ◽  
Complete Resistance ◽  
Hiv Envelope ◽  
Hiv 1

SERINC5 is a potent lentiviral restriction factor that gets incorporated into nascent virions and inhibits viral fusion and infectivity. The envelope glycoprotein (Env) is a key determinant for SERINC restriction, but many aspects of this relationship remain incompletely understood, and the mechanism of SERINC5 restriction remains unresolved. Here, we have used mutants of HIV-1 and HIV-2 to show that truncation of the Env cytoplasmic tail (ΔCT) confers complete resistance of both viruses to SERINC5 and SERINC3 restriction. Critically, fusion of HIV-1 ΔCT virus was not inhibited by SERINC5 incorporation into virions, providing a mechanism to explain how EnvCT truncation allows escape from restriction. Neutralization and inhibitor assays showed ΔCT viruses have an altered Env conformation and fusion kinetics, suggesting that EnvCT truncation dysregulates the processivity of entry, in turn allowing Env to escape targeting by SERINC5. Furthermore, HIV-1 and HIV-2 ΔCT viruses were also resistant to IFITMs, another entry-targeting family of restriction factors. Notably, while the EnvCT is essential for Env incorporation into HIV-1 virions and spreading infection in T cells, HIV-2 does not require the EnvCT. Here, we reveal a mechanism by which human lentiviruses can evade two potent Env-targeting restriction factors but show key differences in the capacity of HIV-1 and HIV-2 to exploit this. Taken together, this study provides insights into the interplay between HIV and entry-targeting restriction factors, revealing viral plasticity toward mechanisms of escape and a key role for the long lentiviral EnvCT in regulating these processes.

scholarly journals Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIVsmm/macEnvelope Glycoprotein Uncouple Antibody-Dependent Cellular Cytotoxicity from Neutralization

mBio ◽  
2019 ◽  
Vol 10 (4) ◽  
Author(s):  
Benjamin von Bredow ◽  
Raiees Andrabi ◽  
Michael Grunst ◽  
Andres G. Grandea ◽  
Khoa Le ◽  
...  
Keyword(s):  
Binding Affinity ◽  
Specific Antibody ◽  
Neutralizing Antibody ◽  
Glycosylation Site ◽  
Antibody Binding ◽  
Cellular Cytotoxicity ◽  
Antibody Dependent Cellular Cytotoxicity ◽  
Broadly Neutralizing Antibody ◽  
Infected Cells ◽  
Hiv 1

ABSTRACTAs a consequence of their independent evolutionary origins in apes and Old World monkeys, human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency viruses of the SIVsmm/maclineage express phylogenetically and antigenically distinct envelope glycoproteins. Thus, HIV-1 Env-specific antibodies do not typically cross-react with the Env proteins of SIVsmm/macisolates. Here we show that PGT145, a broadly neutralizing antibody to a quaternary epitope at the V2 apex of HIV-1 Env, directs the lysis of SIVsmm/mac-infected cells by antibody-dependent cellular cytotoxicity (ADCC) but does not neutralize SIVsmm/macinfectivity. Amino acid substitutions in the V2 loop of SIVmac239 corresponding to the epitope for PGT145 in HIV-1 Env modulate sensitivity to this antibody. Whereas a substitution in a conserved N-linked glycosylation site (N171Q) eliminates sensitivity to ADCC, a lysine-to-serine substitution in this region (K180S) increases ADCC and renders the virus susceptible to neutralization. These differences in function correlate with an increase in the affinity of PGT145 binding to Env on the surface of virus-infected cells and to soluble Env trimers. To our knowledge, this represents the first instance of an HIV-1 Env-specific antibody that cross-reacts with SIVsmm/macEnv and illustrates how differences in antibody binding affinity for Env can differentiate sensitivity to ADCC from neutralization.IMPORTANCEHere we show that PGT145, a potent broadly neutralizing antibody to HIV-1, directs the lysis of SIV-infected cells by antibody-dependent cellular cytotoxicity but does not neutralize SIV infectivity. This represents the first instance of cross-reactivity of an HIV-1 Env-specific antibody with SIVsmm/macEnv and reveals that antibody binding affinity can differentiate sensitivity to ADCC from neutralization.

scholarly journals Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 765
Author(s):  
Alemu Tekewe Mogus ◽  
Lihong Liu ◽  
Manxue Jia ◽  
Diane T. Ajayi ◽  
Kai Xu ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Vaccination Strategy ◽  
Fusion Peptide ◽  
Linear Epitope ◽  
Broadly Neutralizing Antibodies ◽  
Virus Like Particle ◽  
Boost Immunization ◽  
Potential Vaccine ◽  
Hiv Envelope ◽  
Hiv 1

Broadly neutralizing antibodies (bnAbs) isolated from HIV-infected individuals delineate vulnerable sites on the HIV envelope glycoprotein that are potential vaccine targets. A linear epitope within the N-terminal region of the HIV-1 fusion peptide (FP8) is the primary target of VRC34.01, a bnAb that neutralizes ~50% of primary HIV isolates. FP8 has attracted attention as a potential HIV vaccine target because it is a simple linear epitope. Here, platform technologies based on RNA bacteriophage virus-like particles (VLPs) were used to develop multivalent vaccines targeting the FP8 epitope. Both recombinant MS2 VLPs displaying the FP8 peptide and Qβ VLPs displaying chemically conjugated FP8 peptide induced high titers of FP8-specific antibodies in mice. Moreover, a heterologous prime-boost-boost regimen employing the two FP8-VLP vaccines and native envelope trimer was the most effective approach for eliciting HIV-1 neutralizing antibodies. Given the potent immunogenicity of VLP-based vaccines, this vaccination strategy—inspired by bnAb-guided epitope mapping, VLP bioengineering, and prime-boost immunization approaches—may be a useful strategy for eliciting bnAb responses against HIV.

scholarly journals Targeted deletion in the β20–β21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding

Virology ◽  
2008 ◽  
Vol 377 (2) ◽  
pp. 330-338 ◽  
Author(s):  
Ira Berkower ◽  
Chiraag Patel ◽  
Yisheng Ni ◽  
Konstantin Virnik ◽  
Zhexin Xiang ◽  
...  
Keyword(s):  
Binding Site ◽  
Envelope Glycoprotein ◽  
Antibody Binding ◽  
Targeted Deletion ◽  
Envelope Glycoprotein Gp120 ◽  
Cd4 Binding Site ◽  
Glycoprotein Gp120 ◽  
Hiv Envelope

scholarly journals Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Sonu Kumar ◽  
Anita Sarkar ◽  
Pavel Pugach ◽  
Rogier W. Sanders ◽  
John P. Moore ◽  
...  
Keyword(s):  
Structural Dynamics ◽  
Envelope Glycoprotein ◽  
Fusion Peptide ◽  
Hiv 1

scholarly journals HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike

2016 ◽  
Vol 90 (23) ◽  
pp. 10587-10599 ◽  
Author(s):  
Dirk Eggink ◽  
Steven W. de Taeye ◽  
Ilja Bontjer ◽  
Per Johan Klasse ◽  
Johannes P. M. Langedijk ◽  
...  
Keyword(s):  
Conformational Changes ◽  
Viral Entry ◽  
Envelope Glycoprotein ◽  
Drug Targets ◽  
Rapid Development ◽  
Fusion Peptide ◽  
Target Cells ◽  
Gp120 Subunit ◽  
Target Membrane ◽  
Hiv 1

ABSTRACTThe trimeric HIV-1 envelope glycoprotein spike (Env) mediates viral entry into cells by using a spring-loaded mechanism that allows for the controlled insertion of the Env fusion peptide into the target membrane, followed by membrane fusion. Env is the focus of vaccine research aimed at inducing protective immunity by antibodies as well as efforts to develop drugs that inhibit the viral entry process. The molecular factors contributing to Env stability and decay need to be understood better in order to optimally design vaccines and therapeutics. We generated viruses with resistance to VIR165, a peptidic inhibitor that binds the fusion peptide of the gp41 subunit and prevents its insertion into the target membrane. Interestingly, a number of escape viruses acquired substitutions in the C1 domain of the gp120 subunit (A60E, E64K, and H66R) that rendered these viruses dependent on the inhibitor. These viruses could infect target cells only when VIR165 was present after CD4 binding. Furthermore, the VIR165-dependent viruses were resistant to soluble CD4-induced Env destabilization and decay. These data suggest that VIR165-dependent Env proteins are kinetically trapped in the unliganded state and require the drug to negotiate CD4-induced conformational changes. These studies provide mechanistic insight into the action of the gp41 fusion peptide and its inhibitors and provide new ways to stabilize Env trimer vaccines.IMPORTANCEBecause of the rapid development of HIV-1 drug resistance, new drug targets need to be explored continuously. The fusion peptide of the envelope glycoprotein can be targeted by anchor inhibitors. Here we describe virus escape from the anchor inhibitor VIR165. Interestingly, some escape viruses became dependent on the inhibitor for cell entry. We show that the identified escape mutations stabilize the ground state of the envelope glycoprotein and should thus be useful in the design of stabilized envelope-based HIV vaccines.

Role of antibody heavy and light chain interface residues in affinity maturation of binding to HIV envelope glycoprotein

2019 ◽  
Vol 4 (4) ◽  
pp. 737-746 ◽  
Author(s):  
Alberto Cisneros ◽  
Rachel Stecker Nargi ◽  
Erica Hammaker Parrish ◽  
Christian Marie Haliburton ◽  
Jens Meiler ◽  
...  
Keyword(s):  
Binding Affinity ◽  
Heavy Chain ◽  
Light Chain ◽  
Envelope Glycoprotein ◽  
Affinity Maturation ◽  
Antigen Binding ◽  
Glycoprotein P ◽  
Contact Residues ◽  
Hiv Envelope

Optimization of the heavy chain/light chain interface could serve as an important tool for maximizing antibody/antigen binding affinity without altering antigen contact residues.

scholarly journals Inhibition of HIV-1 Envelope Glycoprotein-mediated Cell Fusion by a DL-Amino Acid-containing Fusion Peptide

2004 ◽  
Vol 279 (46) ◽  
pp. 48224-48230 ◽  
Author(s):  
Doron Gerber ◽  
Moshe Pritsker ◽  
Susanne Gunther-Ausborn ◽  
Benitra Johnson ◽  
Robert Blumenthal ◽  
...  
Keyword(s):  
Amino Acid ◽  
Cell Fusion ◽  
Envelope Glycoprotein ◽  
Fusion Peptide ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document